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Abstract
Cystic Fibrosis (CF) is a human genetic disease that results in the accumulation of thick,
sticky mucus in the airways, which results in chronic, life-long bacterial biofilm infections
that are difficult to clear with antibiotics. Pseudomonas aeruginosa lung infection is corre-
lated with worsening lung disease and P. aeruginosa transitions to an antibiotic tolerant
state during chronic infections. Tobramycin is an aminoglycoside currently used to combat
lung infections in individuals with CF. While tobramycin is effective at eradicating P. aerugi-
nosa in the airways of young patients, it is unable to completely clear the chronic P. aerugi-
nosa infections in older patients. A recent report showed that co-addition of tobramycin and
mannitol enhanced killing of P. aeruginosa grown in vitro as a biofilm on an abiotic surface.
Here we employed a model system of bacterial biofilms formed on the surface of CF-derived
airway cells to determine if mannitol would enhance the antibacterial activity of tobramycin
against P. aeruginosa grown on a more clinically relevant surface. Using this model system,
which allows the growth of robust biofilms with high-level antibiotic tolerance analogous to
in vivo biofilms, we were unable to find evidence for enhanced antibacterial activity of tobra-
mycin with the addition of mannitol, supporting the observation that this type of co-treatment
failed to reduce the P. aeruginosa bacterial load in a clinical setting.
Introduction
Cystic fibrosis (CF) is a human genetic disease caused by mutations in the cystic fibrosis trans-
membrane conductance regulator gene (CFTR). In the airways, defects in CFTR result in an
accumulation of thick sticky mucus, which can become chronically infected with bacterial bio-
films that are difficult to clear and are recalcitrant to antibiotic treatment. Of particular concern
is infection with the Gram-negative bacterium Pseudomonas aeruginosa, as infection with P.
aeruginosa is correlated with CF lung function decline and worsening disease. Lung infections
are the primary cause of morbidity and mortality of individuals with cystic fibrosis despite the
near-constant administration of antibiotics [1–3]. Therefore, there is a critical need to develop
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new antibiotics, or alternatively, to develop compounds that render biofilms more sensitive to
current therapies.
Several hypotheses explain the antibiotic tolerance of bacterial biofilms including physical
barriers to antibiotic penetrance from extracellular matrix that biofilms produce [4, 5], the pro-
duction of periplasmic glucans [6], slow growth [7] and/or the presence of metabolically inac-
tive persister cells within a biofilm that are inherently tolerant to antibiotics [8–10]. In regard
to the persister model, Rice and colleagues recently demonstrated a synergistic effect of tobra-
mycin, the frontline CF maintenance therapy antibiotic, and mannitol versus P. aeruginosa
grown in vitro as a biofilm on an abiotic surface [10]. The authors attribute this increase in
tobramycin sensitivity to a stimulation of the persister cells from dormancy as had been previ-
ously described for E. coli [9].
Biofilms formed on abiotic surfaces (plastic or glass), while a relevant model for medical
device implants, may not accurately represent the biofilms that form in the CF lung, as they
may miss important contributions from the host, including the release of nutrients such as iron
and the availability of a biotic substratum to facilitate bacterial colonization [11–14]. In this
study, we tested if mannitol treatment would render P. aeruginosamore sensitive to tobramy-
cin when grown as a biofilm on the surface of airway cells derived from a cystic fibrosis patient
homozygous for the ΔF508 allele of CFTR. P. aeruginosa grown in this model system recapitu-
lates several key aspects of CF lung disease, including robust biofilm formation compared to
biofilms formed on non-CF airways cells as well as high-level antibiotic tolerance of these bio-
films [12, 13]. Based on our studies, we were unable to find any evidence for enhanced antibac-
terial activity of tobramycin with mannitol co-treatment on eight strains of P. aeruginosa,
including five CF clinical isolates, using this model system of bacterial biofilm formation on CF
airway cells. These results support the observation that a mannitol-tobramycin co-treatment
does not reduce bacterial load in patients who have been co-administered [15] and highlight
the differences in antibiotic tolerance of biofilms formed on biotic and abiotic surfaces.
Materials and Methods
Bacterial strains and growth conditions
Bacterial strains used in this study are listed in Table 1. P. aeruginosa strains were routinely cul-
tured in lysogeny broth (LB) liquid medium shaking at 37°C or on LB agar incubated at 37°C.
Minimum inhibitory concentration (MIC) of tobramycin for P. aeruginosa strains were mea-
sured using Biomerieux E-test strips according to manufacture’s instructions.
Table 1. Strains used in this study.
Strain number Source Tob MIC (μg/mL)a Mucoid Reference
P. aeruginosa
SMC232 Laboratory strain, P. aeruginosa PA14 0.75 No [16]
SMC1585 CF sputum isolate 0.125 Yes [17]
SMC1587 CF sputum isolate 8.0 No [17]
SMC1595 CF sputum isolate 1.5 No [17]
SMC1596 CF sputum isolate 1.0 No [17]
SMC5450 CF sputum isolate 1.0 Yes [17]
SMC84 P. aeruginosa PAO1 0.5 No [18]
SMC407 P. aeruginosa FRD1 1.0 Yes [17, 19]
a Minimum inhibitory concentration of tobramycin for P. aeruginosa strains as measured by Biomerieux E-test strips according to manufacture’s
instructions.
doi:10.1371/journal.pone.0141192.t001
No Additive Effect of Mannitol on Tobramycin Antibacterial Activity
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Tissue culture cultivation
The cystic fibrosis bronchial epithelial (CFBE) cell line used in this study over expresses
F508del-CFTR via stable lentiviral transfection of human bronchial epithelial cells [20]
(CFBE41o-, isolated from a CF patient who was homozygous for ΔF508-CFTR mutation),
which were originally immortalized and characterized by Gruenert and colleagues [21, 22].
CFBE cells were the generous gift of J.P. Clancy. IRB approval was not required for the use of
this cell line. CFBE cells were cultivated as previously described [12, 13]. Briefly, CFBE cells
were seeded into 24-well plates at 50,000 cells/well and fed every other day with minimal essen-
tial medium (MEM, Life Technologies) supplemented with 2 mM L-glutamine, 50 U/mL Peni-
cillin, 50 μg/mL Streptomycin, 2μg/mL Puromycin, 5 μg/mL Plasmocin, and 10% Fetal Bovine
Serum until confluent and had formed tight junctions [5–7 days).
Biofilm antibiotic assay on airway cells
Biofilm antibiotic assays were performed as previously described [12, 13]. Briefly, an overnight
culture of P. aeruginosa was washed and resuspended in 1 mL of MEM. P. aeruginosa inoculum
was prepared to an OD600 of 0.05 (~5x10
7 CFUs/mL) in MEM supplemented with 2 mM L-
glutamine. Next, 0.5 mL of the P. aeruginosa suspension was gently added to each well of CFBE
cells that had been washed twice with MEM. Cultures were incubated one hour at 37°C, 5%
CO2. One hour post-inoculation, unattached cells were removed by aspiration and the medium
was replaced with MEM supplemented with 2 mM L-glutamine and 0.4% arginine. Six hours
post inoculation, the unattached bacteria were removed by aspiration to remove the planktonic
fraction of bacteria; the biofilm fraction was washed once with MEM supplemented with 2 mM
L-glutamine and 0.4% arginine and incubated with or without 8 μg/mL tobramycin and/or 60
mMmannitol, as indicated, in MEM supplemented with 2 mM L-glutamine and 0.4% arginine.
Twenty-one hours post-inoculation, planktonic fractions were removed. MEM was added to
wells and the biofilms disrupted by scraping with a pipette tip. The biofilm-grown bacteria
were serially diluted and then plated on LB and incubated overnight at 37°C. After overnight
incubation, resulting colonies were counted and CFUs were determined. CFUs/well were log10
transformed. Log10 transformed data was used for all figures and statistical analyses.
Biofilm antibiotic assay on plastic
An overnight culture of P. aeruginosa was washed and resuspended in 1 mL of MEM. P. aerugi-
nosa inoculum was prepared to an OD600 of 0.05 (~5x10
7 CFUs/mL) in MEM supplemented
with 2 mM L-glutamine. Next, 0.1 mL of the P. aeruginosa suspension was gently added to
each well of a 96-well culture plate. Cultures were incubated one hour at 37°C, 5% CO2. One
hour post-inoculation, unattached cells were removed and the medium was replaced with
MEM supplemented with 2 mM L-glutamine and 0.4% arginine. Six hours post inoculation,
the unattached bacteria were removed and the biofilm fraction was incubated with or without
80 μg/mL tobramycin and/or 60 mMmannitol in MEM supplemented with 2 mM L-glutamine
and 0.4% arginine. Twenty-one hours post-inoculation, planktonic fractions were removed.
MEM was added to wells and biofilms were disrupted using a solid pin multi-blot replicator.
The biofilm-grown bacteria were serially diluted and then plated on LB and incubated over-
night at 37°C. After overnight incubation, resulting colonies were counted and CFUs were
determined. CFUs/well were log10 transformed. Log10 transformed data was used for all figures
and statistical analyses.
No Additive Effect of Mannitol on Tobramycin Antibacterial Activity
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Cytotoxicity Assay
Cytotoxicity was measured as fraction of lactate dehydrogenase (LDH) release using the Cyto-
Tox 96 Non-radioactive Cytotoxicity Kit (Promega) according to the manufacturer’s instruc-
tions. CFBE cells were incubated with 0, 40 or 60 mMmannitol (dissolved in MEM) for 24
hours at 37°C, 5% CO2. Supernatants were collected and used in the CytoTox 96 Non-radioac-
tive Cytotoxicity Kit. Cells treated with Triton X-100 detergent served as the total lysis control.
Fraction cytotoxicity was determined by dividing the absorbance at 450 nm of each sample
(OD450) by the OD450 of the total lysis control.
Results
Mannitol co-treatment does not increase the susceptibility of a laboratory
strain of P. aeruginosa to tobramycin
To test the hypothesis that mannitol would increase the antibacterial activity of tobramycin on
CF airway cell-grown biofilms of P. aeruginosa, we first measured the cytotoxic effect of man-
nitol on CF airways cells to ensure that the dose of mannitol used in subsequent studies did not
damage the host cells. In these studies, CF-derived bronchial epithelial (CFBE) cells, which are
homozygous for the ΔF508 mutation in CFTR, were used as the substratum to grow the P. aer-
uginosa biofilms. To assess cytotoxicity of mannitol, CFBE cells were incubated with increasing
concentrations of mannitol, or medium alone as a control, for 24 hours. Supernatants were col-
lected, bacteria were removed by centrifugation and clarified supernatants were used to deter-
mine cytotoxicity, which was expressed as the fraction of the cytoplasmic enzyme LDH
released, using a colorimetric assay. LDH activity was normalized to a total lysis control, set at
1.0, wherein the host cells were treated with Triton-X 100, a detergent used to burst cells open.
Treatment with 40 mM or 60 mMmannitol, which falls within the range of concentrations
used in previous studies with abiotic biofilms [10], resulted in low cytotoxicity (less than 20%
of total lysis), comparable to treatment with tissue culture medium alone (Fig 1A). Because the
higher dose had minimal cytotoxicity, we used 60 mMmannitol in all subsequent assays.
To test if mannitol treatment could sensitize P. aeruginosa to tobramycin treatment in the
context of a biofilm formed on the surface of airway cells, we established P. aeruginosa strain
PA14 biofilms on the surface of CF airway cells as previously described [12, 13]. Biofilms were
established for six hours before treatment with medium, tobramycin, mannitol or co-treatment
with tobramycin and mannitol. After fifteen hours of treatment, the viability of P. aeruginosa
growing as a biofilm was determined by colony counts. Treatment with 60 mMmannitol alone
resulted in similar viability to treatment with medium alone. Treatment with 8 μg/mL of tobra-
mycin resulted in a 3.3-log10 reduction in viability of biofilm grown bacteria. Co-treatment of
P. aeruginosa grown as a biofilm on CFBE cells with 8 μg/mL of tobramycin and 60 mMman-
nitol resulted in a 2.9-log10 reduction in viability; a difference which is not statistically signifi-
cant from treatment with tobramycin alone, suggesting that mannitol does not sensitize P.
aeruginosa to tobramycin (Fig 1B).
Mannitol co-treatment does not increase the susceptibility of CF clinical
isolates of P. aeruginosa to tobramycin
The laboratory strain P. aeruginosa PA14, while a recent isolate of this microbe, was obtained
from a burn wound and may not accurately reflect the strains of P. aeruginosa found in the air-
ways of individuals with CF. We therefore examined the effects of mannitol co-treatment with
tobramycin on 5 clinical strains isolated from sputum of individuals with CF (Table 1). These
strains exhibited a range of tobramycin resistance and mucoidy as previously characterized
No Additive Effect of Mannitol on Tobramycin Antibacterial Activity
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[17]. Strains SMC1585 and 5450 are mucoid, while strains SMC1587, 1595 and 1596 are non-
mucoid; the tobramycin MIC for planktonically grown cultures of these strains is shown in
Table 1.
There was no reduction of P. aeruginosa viability from mannitol treatment alone compared
to treatment with medium alone for any of the clinical isolates tested (Fig 2). Additionally,
there was no reduction of P. aeruginosa viability in biofilms co-treated with mannitol and
tobramycin (at 8 μg/ml, the same concentration tested for the laboratory isolate) compared to
treatment with tobramycin alone (Fig 2A). These results suggest that mannitol does not sensi-
tize P. aeruginosa isolated from the airways of individuals with CF to tobramycin when grown
as a biofilm on CF airway cells.
As an additional control, we also investigated the impact of mannitol on biofilms of P. aeru-
ginosa PAO1 (a lab strain) and P. aeruginosa FRD1 (a clinical mucoid strain) treated with
tobramycin. Mannitol did not enhance tobramycin-mediated killing of either of these strains
(Fig 2B). Finally, we replicated the original finding of Rice and colleagues [10]. As was origi-
nally reported, when the biofilm of P. aeruginosa PAO1 was grown on plastic, the addition of
mannitol enhanced tobramycin-mediated killing by ~100-fold (Fig 2C). It is important to note
Fig 1. Mannitol does not sensitize non-mucoid, laboratory strain P. aeruginosa PA14 to tobramycin.
A. Mannitol is minimally cytotoxic to CFBE cells. Normalized cytotoxicity as measured by fraction of LDH
release. Cytotoxicity was measured after 24 hours of treatment with 0, 40 or 60 mMmannitol as indicated.
Cells lysed with Triton X-100 served as a control to determine total lysis. Columns indicate mean of at least
three biological replicates, error bars indicate standard deviation (S.D.). **, P<0.01, comparison of indicated
sample to total lysis control by ordinary one-way ANOVA with Tukey’s post test for multiple comparisons. B.
Viability of P. aeruginosa PA14 grown as a biofilm on CFBE cells after treatment with 0 μg/mL tobramycin
(open bars), 8 μg/mL tobramycin (hatched bars), 0 mMmannitol (white bars), 60 mMmannitol (gray bars) or
co-treatment with 8 μg/mL tobramycin and 60 mMmannitol, as indicated. Columns indicate mean of at least
three biological replicates, error bars indicate S.D. ***, P<0.001 by ordinary one-way ANOVA with Tukey’s
post test for multiple comparisons. There is no significant difference between P. aeruginosa PA14 treated with
tobramycin +/- mannitol.
doi:10.1371/journal.pone.0141192.g001
No Additive Effect of Mannitol on Tobramycin Antibacterial Activity
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Fig 2. Mannitol does not sensitize P. aeruginosa clinical isolates grown as biofilms on CF airway cells to tobramycin. A. Viability of P. aeruginosa
clinical isolates grown as biofilms on CFBE cells and treated with 0 μg/mL tobramycin (open bars), 8 μg/mL tobramycin (hatched bars), 0 mMmannitol (white
bars), 60 mMmannitol (gray bars) or co-treatment with 8 μg/mL tobramycin and 60 mMmannitol, as indicated. Columns indicate mean of at least three
biological replicates, error bars indicate S.D. **, P<0.01 by ordinary one-way ANOVA with Tukey’s post test for multiple comparisons. B. The viability of
strains P. aeruginosa PAO1 (left) and FRD1 (right) as biofilms on CFBE cells and treated with 0 μg/mL tobramycin (open bars), 8 μg/mL tobramycin (hatched
bars), 0 mMmannitol (white bars), 60 mMmannitol (gray bars) or co-treatment with 8 μg/mL tobramycin and 60 mMmannitol, as indicated. **, P<0.01 or
***, P<0.001 by ordinary one-way ANOVA with Tukey’s post test for multiple comparisons. ns, not significant compared to tobramycin treatment in the
absence of mannitol. C. The viability of strain P. aeruginosa PAO1 as a biofilm on plastic and treated with 0 μg/mL tobramycin (open bars), 80 μg/mL
tobramycin (hatched bars), 0 mMmannitol (white bars), 60 mMmannitol (gray bars) or co-treatment with 80 μg/mL tobramycin and 60 mMmannitol, as
indicated. *, P<0.05 compared to treatment with 80 μg/mL tobramycin with no mannitol. **, P<0.01 or ***, P<0.001 by ordinary one-way ANOVA with
Tukey’s post test for multiple comparisons.
doi:10.1371/journal.pone.0141192.g002
No Additive Effect of Mannitol on Tobramycin Antibacterial Activity
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that while in our experiments we saw substantially more killing of P. aeruginosa PAO1 treated
with tobramycin alone than was observed by Rice, et al. [10] we still observed the originally
reported mannitol-enhanced killing.
Discussion
The bacteria that chronically infect the lungs of individuals with CF are recalcitrant to anti-
biotics. One hypothesis for this tolerance to treatment is that the bacteria are in a metaboli-
cally dormant state and are therefore intrinsically resistant to antibiotic pressure [8].
Because this tolerance is not genetically encoded, if these cells could be brought out of dor-
mancy, they would then be sensitive to antibiotic killing. Such examples have been shown in
E. coli [9] and in P. aeruginosa [10]. In the case of P. aeruginosa, a sub-set of strains of this
microbe (strains PAO1 and FRD) grown as biofilms formed on a abiotic (plastic) surface
were approximately 1000-fold more sensitive to tobramycin treatment with co-administra-
tion of mannitol and tobramycin. We replicated that finding here with a biofilm of P. aerugi-
nosa PAO1 grown on plastic. However, an additional clinical isolate 18A was resistant to
tobramycin, and co-administration of mannitol and tobramycin did not sensitize this strain,
suggesting that tobramycin sensitization by mannitol is strain specific and is not
generalizable.
To address whether the synergy of mannitol and tobramycin might be relevant to a CF
patient population, we used our in vitro model system of bacterial biofilm formation on CF
airway cells to assess whether this synergy also occurs on a more clinically relevant surface.
P. aeruginosa grown in our model system recapitulate several key aspects of chronic biofilm
formation, including formation of biofilm-like microcolonies, expression of genes associ-
ated with biofilm growth, induction of quorum sensing, the requirement for genes neces-
sary for biofilm formation on abiotic surfaces and, of clinical importance, high-level
antibiotic tolerance consistent with biofilms in clinical settings [12, 13]. Using this system,
we were unable to recapitulate the sensitization effect that mannitol gave to tobramycin
treated biofilms grown on plastic. This absence of synergy held true for the lab strains P.
aeruginosa PA14 and PAO1, the well-characterized mucoid clinical isolate P. aeruginosa
FRD1 as well as five other clinical strains of P. aeruginosa isolated from individuals with
CF, including strains showing planktonic tobramycin resistance as well as mucoid and non-
mucoid strains.
Mannitol is currently utilized as a therapeutic that hydrates mucus allowing for increased
mucociliary and cough clearance of retained secretions in the airways of individuals with CF
[15, 23]. Our model system does not produce mucus, therefore we cannot test the effect that
mucus viscosity/ hydration has on tobramycin efficacy. It is formally possible that better hydra-
tion of the airways may allow better penetrance and therefore better effectiveness of antibiotics.
However, in the clinical trial, no change in P. aeruginosa load was observed in patients given
mannitol versus placebo control despite maintaining their current CF therapies including
inhaled antibiotics [15], supporting our findings that tobramycin and mannitol do not syner-
gize in the treatment of P. aeruginosa biofilms formed on airway cells.
Experiments presented here suggest that the mechanism of action of mannitol via stimula-
tion of P. aeruginosa out of a dormant state and into metabolically active one that is sensitive
to tobramycin, as suggested by Rice et al. [10], is unlikely to be occurring in biofilms formed on
biotic surfaces. Additionally, our results illustrate that biofilms grown on biotic surfaces are dis-
tinct from biofilms grown on plastic, as has been previously reported [11–13] and highlights
the cost and time savings achieved by using biofilms formed on biotic surfaces as an important
tool in preclinical studies for drug discovery.
No Additive Effect of Mannitol on Tobramycin Antibacterial Activity
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